GSK

Company

Last mentioned: 1d ago

Share

Across the most recent 7 stories covering GSK — 43% negative, 57% neutral sentiment, averaging 6.6/10 impact.

This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

Timeline

  1. Data Review

    Health authorities begin reviewing uptake rates and digital health records.

  2. Peak Delivery Phase

    High-volume vaccination sessions scheduled to capture maximum student participation.

  3. Rollout Launch

    Vaccination clinics open on campus for the first cohort of 5,000 students.

  4. Strain Confirmation

    Laboratory results confirm Meningitis B as the causative agent in two fatal cases.

  5. Public Health Mobilization

    Coordinated media briefings and emergency triage protocols established in affected regions.

  6. National Alert Issued

    Health chiefs issue an 'unprecedented' warning to the NHS network.

  7. Initial Cluster Detection

    Regional health boards report unusual spikes in bacterial meningitis cases.

  8. Outbreak Detected

    Initial cases reported with severe symptoms; public health investigation launched.

  9. FY 2025 Earnings

    Wave and Collegium release full-year financial results and 2026 guidance.

  10. Anticipated Filing

    Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.

  11. RNA Editing Milestone

    WVE-006 demonstrates successful RNA editing in AATD patients.

  12. DMD Breakthrough

    Wave reports industry-leading dystrophin expression for WVE-N531.

  13. Vaccine Integration

    UK becomes first to add MenB vaccine (Bexsero) to routine infant schedule.

Stories mentioning GSK 7

About GSK coverage

This page surfaces every story mentioning GSK across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.

Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.

What you seeWhat it tells you
Story countNumber of distinct stories where GSK was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.